220 related articles for article (PubMed ID: 25902888)
1. Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.
Akagi S; Nakamura K; Miura D; Saito Y; Matsubara H; Ogawa A; Matoba T; Egashira K; Ito H
Int Heart J; 2015 May; 56(3):354-9. PubMed ID: 25902888
[TBL] [Abstract][Full Text] [Related]
2. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.
Akagi S; Nakamura K; Matsubara H; Kondo M; Miura D; Matoba T; Egashira K; Ito H
J Cardiovasc Pharmacol; 2016 Apr; 67(4):290-8. PubMed ID: 26745002
[TBL] [Abstract][Full Text] [Related]
3. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.
Pankey EA; Thammasiboon S; Lasker GF; Baber S; Lasky JA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Nov; 305(9):H1288-96. PubMed ID: 23997103
[TBL] [Abstract][Full Text] [Related]
4. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor up-regulates Ca
Yamamura A; Nayeem MJ; Al Mamun A; Takahashi R; Hayashi H; Sato M
FASEB J; 2019 Jun; 33(6):7363-7374. PubMed ID: 30865840
[TBL] [Abstract][Full Text] [Related]
6. A lymphocyte-dependent mode of action for imatinib mesylate in experimental pulmonary hypertension.
Ormiston ML; Deng Y; Rundle N; Bendjelloul F; Tsoporis JN; Parker TG; Stewart DJ; Courtman DW
Am J Pathol; 2013 May; 182(5):1541-51. PubMed ID: 23518411
[TBL] [Abstract][Full Text] [Related]
7. Role of Src tyrosine kinases in experimental pulmonary hypertension.
Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
[TBL] [Abstract][Full Text] [Related]
8. PAR-2 inhibition reverses experimental pulmonary hypertension.
Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
[TBL] [Abstract][Full Text] [Related]
9. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.
Nakamura K; Akagi S; Ogawa A; Kusano KF; Matsubara H; Miura D; Fuke S; Nishii N; Nagase S; Kohno K; Morita H; Oto T; Yamanaka R; Otsuka F; Miura A; Yutani C; Ohe T; Ito H
Int J Cardiol; 2012 Aug; 159(2):100-6. PubMed ID: 21376411
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W
BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension.
Chen L; Nakano K; Kimura S; Matoba T; Iwata E; Miyagawa M; Tsujimoto H; Nagaoka K; Kishimoto J; Sunagawa K; Egashira K
Hypertension; 2011 Feb; 57(2):343-50. PubMed ID: 21220711
[TBL] [Abstract][Full Text] [Related]
12. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
Perros F; Montani D; Dorfmüller P; Durand-Gasselin I; Tcherakian C; Le Pavec J; Mazmanian M; Fadel E; Mussot S; Mercier O; Hervé P; Emilie D; Eddahibi S; Simonneau G; Souza R; Humbert M
Am J Respir Crit Care Med; 2008 Jul; 178(1):81-8. PubMed ID: 18420966
[TBL] [Abstract][Full Text] [Related]
13. Isorhynchophylline protects against pulmonary arterial hypertension and suppresses PASMCs proliferation.
Guo H; Zhang X; Cui Y; Deng W; Xu D; Han H; Wang H; Chen Y; Li Y; Wu D
Biochem Biophys Res Commun; 2014 Jul; 450(1):729-34. PubMed ID: 24950404
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension.
Kimura S; Egashira K; Chen L; Nakano K; Iwata E; Miyagawa M; Tsujimoto H; Hara K; Morishita R; Sueishi K; Tominaga R; Sunagawa K
Hypertension; 2009 May; 53(5):877-83. PubMed ID: 19307469
[TBL] [Abstract][Full Text] [Related]
15. [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
Li XL; Guan RJ; Xu QH; Wu ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):247-53. PubMed ID: 21609531
[TBL] [Abstract][Full Text] [Related]
16. Regulatory effects of Prohibitin 1 on proliferation and apoptosis of pulmonary arterial smooth muscle cells in monocrotaline-induced PAH rats.
Cao YY; Ba HX; Li Y; Tang SY; Luo ZQ; Li XH
Life Sci; 2020 Jun; 250():117548. PubMed ID: 32173312
[TBL] [Abstract][Full Text] [Related]
17. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension.
Xi X; Liu S; Shi H; Yang M; Qi Y; Wang J; Du J
Cardiovasc Toxicol; 2014 Dec; 14(4):368-78. PubMed ID: 24825325
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
Hosokawa S; Haraguchi G; Sasaki A; Arai H; Muto S; Itai A; Doi S; Mizutani S; Isobe M
Cardiovasc Res; 2013 Jul; 99(1):35-43. PubMed ID: 23631839
[TBL] [Abstract][Full Text] [Related]
19. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.
Tu L; De Man FS; Girerd B; Huertas A; Chaumais MC; Lecerf F; François C; Perros F; Dorfmüller P; Fadel E; Montani D; Eddahibi S; Humbert M; Guignabert C
Am J Respir Crit Care Med; 2012 Oct; 186(7):666-76. PubMed ID: 22798315
[TBL] [Abstract][Full Text] [Related]
20. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
